-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Cellebrite DI, Maintains $24 Price Target

Benzinga·06/06/2025 11:16:01
Listen to the news
Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:CLBT) with a Buy and maintains $24 price target.